An urea breath test (UBT) is a non-invasive, highly accurate diagnostic procedure used to detect active Helicobacter pylori (H. pylori) infection in the stomach. It is recommended by leading gastroenterology guidelines as the preferred initial test both before and after eradication therapy due to its excellent sensitivity and specificity, patient comfort, and rapid results.

Principle and Mechanism

H. pylori produces large amounts of the enzyme urease, which hydrolyzes urea into ammonia and carbon dioxide. During the UBT:

  1. A baseline breath sample is collected.

  2. The patient ingests urea labeled with either non-radioactive carbon-13 (^13C) or radioactive carbon-14 (^14C).

  3. After 15–30 minutes, a second breath sample is collected.

  4. Detection of isotope-labeled CO₂ in the post-urea sample indicates urease activity—and thus the presence of H. pylori—in the stomach.

The difference between pre- and post-ingestion isotope levels is compared against a cut-off value to determine a positive or negative result. ^13C-UBT is preferred in most settings due to its non-radioactive nature and is safe for children and pregnant women.

Preparation

To ensure accurate results:

  • Fasting: No food or drink for 4–6 hours before the test.

  • Medication cessation:

    • Stop antibiotics at least 4 weeks prior.

    • Discontinue proton pump inhibitors (e.g., omeprazole, lansoprazole) 2 weeks before.

    • Avoid bismuth compounds (e.g., Pepto-Bismol) 2 weeks before.

  • Oral hygiene: Rinse mouth immediately before the test to reduce interference from oral urease.

Procedure

  1. Baseline sample: Exhale into a collection bag or analyzer to measure baseline CO₂.

  2. Urea ingestion: Drink a lemon-flavored or citric acid–containing solution with labeled urea (or swallow a capsule).

  3. Waiting period: Rest for 15–30 minutes to allow gastric urease activity.

  4. Post-dose sample: Exhale into the collection device again.

  5. Analysis:

    • ^13C samples: measured by isotope ratio mass spectrometry or nondispersive infrared spectrometry.

    • ^14C samples: measured by scintillation counting.

Total test duration is approximately 30–40 minutes, after which patients may resume normal activities immediately.

Interpretation of Results

  • Positive: Significant rise in labeled CO₂ in the second sample indicates active H. pylori infection.

  • Negative: No significant change suggests absence of infection.

Results are typically available within minutes if processed on-site, or within 1–2 days if sent to a reference laboratory.

Diagnostic Accuracy

Meta-analyses show both ^13C and ^14C UBTs have:

  • Sensitivity: ≈ 95–97%

  • Specificity: ≈ 91–94%

^13C-UBT: sensitivity 0.96 (95% CI 0.95–0.97), specificity 0.94 (95% CI 0.92–0.95)
^14C-UBT: sensitivity 0.97 (95% CI 0.95–0.98), specificity 0.91 (95% CI 0.87–0.94).

Advantages

  • Non-invasive: No endoscopy required.

  • High accuracy: Detects only active infection.

  • Rapid results: Office-based testing available.

  • Patient comfort: Minimal discomfort and quick procedure.

Limitations

  • Medication interference: Recent antibiotics, PPIs, or bismuth can cause false negatives; testing should be delayed accordingly.

  • Equipment needs: Requires specialized analyzers and, for ^14C, infrastructure to handle radioactive materials.

  • Cost: More expensive than serology or stool antigen tests.

  • Heterogeneity factors: Oral flora urease, gastric emptying, meal composition, and individual patient factors may affect accuracy.

Clinical Applications

  • Initial diagnosis: In dyspeptic patients suspected of H. pylori infection.

  • Post-treatment monitoring: Confirm eradication at least 4 weeks after antibiotics and 2 weeks after stopping PPIs.

  • Screening in at-risk populations: e.g., family members of infected individuals, patients with peptic ulcer disease, or before non-steroidal anti-inflammatory therapy.

1
Appointment